Attached files
| file | filename |
|---|---|
| EX-31.1 - EXHIBIT 31.1 - Lotus Biotech Development Corp. | exhibit311.htm |
| 10-Q - FORM 10-Q - Lotus Biotech Development Corp. | f20161121_lotus10qsep2016bil.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Lotus Bio-Technology Development Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “report”), I, Michael Palethorpe, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
|
|
|
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
|
| (2) | The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated this 21st day of November, 2016.
|
|
| /s/ Michael Palethorpe |
| Michael Palethorpe |
| Chief Executive Officer and Chief Financial Officer |